08:40 AM EDT, 03/24/2025 (MT Newswires) -- Anixa Biosciences ( ANIX ) said Monday that it received a notice of allowance from the US Patent and Trademark Office for its patent application covering its potential ovarian cancer vaccine.

The patent application includes claims related to methods for eliciting an immune response targeting the anti-Mullerian hormone receptor, type II, or AMHR2, a target for ovarian cancer prevention and treatment, Anixa said.

The allowed claims include methods of administering an immunogenic composition consisting of a nucleic acid encoding the AMHR2 polypeptide, the company said.

Anixa said its ovarian cancer vaccine is being developed in collaboration with the Cleveland Clinic and the National Cancer Institute.

Shares of Anixa were up more than 3% in recent premarket activity.